D.E. Shaw & Co
AGRX

D.E. Shaw & Co’s Agile Therapeutics AGRX Stock Holding History

D.E. Shaw & Co’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,099
Closed -$460K – 5964
2022
Q1 		$460K Buy
1,099
+18
+2% +$11.5K ﹤0.01% 4420
2021
Q4 		$1.05M Buy
1,081
+920
+571% +$1.3M ﹤0.01% 3890
2021
Q3 		$310K Buy
161
+114
+243% +$258K ﹤0.01% 4335
2021
Q2 		$126K Sell
47
-4
-8% -$13.2K ﹤0.01% 4522
2021
Q1 		$212K Sell
51
-8
-14% -$43.2K ﹤0.01% 3836
2020
Q4 		$336K Buy
59
+32
+119% +$188K ﹤0.01% 3563
2020
Q3 		$162K Buy
+27
New +$155K ﹤0.01% 3636

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

D.E. Shaw & Co's AGRX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Agile Therapeutics (AGRX) in Q2 2022, closing a stake of 1,099 shares — an estimated $460K sold.

D.E. Shaw & Co first reported a position in AGRX in Q3 2020 and held it in 7 quarters. The position peaked at $1.05M in Q4 2021. 19 funds tracked by Wall St. Rank hold AGRX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Agile Therapeutics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,099 Agile Therapeutics shares in Q2 2022, an estimated $460K.
  • D.E. Shaw & Co first reported a position in Agile Therapeutics in Q3 2020 and held it in 7 quarters.
  • D.E. Shaw & Co's Agile Therapeutics position peaked at $1.05M in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.